ReviewNutrients2024
Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.
Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A narrative review of nutritional components, health effects, and disease prevention mechanisms of dairy products.Frontiers in public health · 2026Pooled it
- Probiotics in epilepsy treatment: a meta-analysis of efficacy and safety.Frontiers in microbiology · 2025Pooled it
- A bibliometric analysis of global research status and trends in irritable bowel syndrome and gut microbiota metabolites.Frontiers in microbiology · 2025Pooled it
- Saccharomyces boulardii's impact on pediatric diarrhea-predominant irritable bowel syndrome: animal model findings.Pediatric research · 2026Trial
- Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome: a double-blind, randomized controlled trial.Frontiers in cellular and infection microbiology · 2025Trial
- A Novel Mixture ContainingInternational journal of molecular sciences · 2026Article
- Decoding Microbiota-Immune Interplay in Viral Pathogenesis: Toward Next-Generation Antiviral Therapies.Probiotics and antimicrobial proteins · 2026Review
- Construction of an engineered Escherichia coli strain with enhanced intestinal colonization and anti-inflammatory efficacy in colitis.Cellular & molecular immunology · 2026Article
- The Wine Ecosystem as a Reservoir for Potential Probiotics: A Comparative In Vitro Evaluation ofFoods (Basel, Switzerland) · 2026Article
- From niche to niche: investigating microbial communities and their specialised metabolite gene clusters in human microbiomes.World journal of microbiology & biotechnology · 2026Article
- Article
- Abdominal massage alleviates IBS-D by modulating the gut microbiota and suppressing the LPS/TLR4/NF-κB/MLCK pathway.Frontiers in microbiology · 2026Article
- What is the Impact of Dopamine D2 Receptor in the Brain-Gut Axis? A Narrative Review of the Mechanism Based on Gut Microbiota in Modulating Emotion and Behavior.Alpha psychiatry · 2025Review
- Exclusive Effects of Moxibustion on Gut Microbiota: Protocol for a Focused Systematic Review and Meta-Analysis.JMIR research protocols · 2025Article
- Effect ofNutrients · 2025Article
- The hidden genetic and microbial networks connecting neuropsychiatric and digestive disorders.Computational and structural biotechnology journal · 2025Article
- The application of fecal microbiota transplantation in Parkinson's disease.Frontiers in aging neuroscience · 2025Review
- Targeting γ-aminobutyric acid pathways in irritable bowel syndrome: bridging central nervous system, enteric dysfunction, and the microbiota-gut-brain axis.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal discomfort, bloating, cramping, flatulence, and changes in bowel movements. The pathophysiology of IBS involves a complex interaction between motor, sensory, microbiological, immunological, and psychological factors. Diversity, stability, and metabolic activity of the gut microbiota are frequently altered in IBS, thus leading to a situation of gut dysbiosis. Therefore, the use of probiotics and probiotic-derived metabolites may be helpful in balancing the gut microbiota and alleviating irritable bowel syndrome symptoms. This review aimed to report and consolidate recent progress in understanding the role of gut dysbiosis in the pathophysiology of IBS, as well as the current studies that have focused on the use of probiotics and their metabolites, providing a foundation for their potential beneficial effects as a complementary and alternative therapeutic strategy for this condition due to the current absence of effective and safe treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.